Work

Endogenous CD28 takes the driver’s seat in 4-1BB co-stimulated CAR T cells

Year: 2026

Type: article

Abstract: Inhibiting the pro-survival CD28 signal on multiple myeloma (MM) cells by blocking its interaction with B7 proteins, CD86 and CD80, can resensitize refractory MM to chemotherapy.1 In our recent article published in Blood Cancer Discovery,2 we sought to extend these findings to chimeric antigen receptor (CAR) T cell therapy using mouse models of MM. Contrary to expectations, CD28 blockade limited persistent tumor control by 4-1BB co-stimulated (BBζ) CAR T cells, revealing a novel role for endogenous CD28 in supporting CAR T cell efficacy (Figure 1).

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201192

Authors: Jason H. Tong, Scott H. Olejniczak

Institution: Roswell Park Comprehensive Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900